Skip to main content

Table 2 Most common adverse events considered associated with treatment occurring in ≥3% of either treatment group*

From: Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: A double-blind placebo-controlled trial

  Placebo (n = 85)
Incidence, n (%)
Pregabalin (n = 82)
Incidence, n (%)
Peripheral edema 27 (31.8) 30 (36.6)
Dizziness 5 (5.9) 27 (32.9)
Weight gain 1 (1.2) 12 (14.6)
Somnolence 5 (5.9) 11 (13.4)
Asthenia 1 (1.2) 8 (9.8)
Ataxia 0 4 (4.9)
Dry mouth 1 (1.2) 4 (4.9)
Abdomen enlarged 4 (4.7) 3 (3.7)
Edema 0 3 (3.7)
Euphoria 0 3 (3.7)
Thinking abnormal 0 3 (3.7)
  1. *Associated AEs are those considered by the investigator as possibly, probably, or definitely related to study drug and those with insufficient information to determine a relationship.